Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF9001 in advanced solid tumors
NCT05597839Phase 2Completed
- Sponsor
- Dragonfly Therapeutics
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of df9001 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more (6 arms), sponsored by Dragonfly Therapeutics. Primary endpoints: Treatment-Related Adverse Events, Adverse Events and 2 more. Started Nov 2022; status: completed.
02
Drugs
df9001
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)solid tumor
Beyond the preview
Go deeper on NCT05597839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597839.